Drug intelligence / Profile preview

HP-5000

Development stage: Unknown
Lead developer: Noven Pharmaceuticals
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

HP-5000 is a topical patch containing Diclofenac Sodium, a nonsteroidal anti-inflammatory drug (NSAID). Developed by Noven Pharmaceuticals, Inc. and Hisamitsu Pharmaceutical, it is designed to alleviate pain and inflammation by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. The drug has undergone studies to evaluate its potential for skin irritation and sensitization, and has been investigated for the treatment of osteoarthritis pain of the knee.

Other names: HP-5000 Topical PatchHP5000 Topical PatchHP 5000 Topical PatchDiclofenac Sodium Topical Systempain relief and anti-inflammatory patch

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on HP-5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-5000.

Explore the full profile